News
Trial results, approvals, pricing changes, safety findings and market moves across peptides and GLP-1 medications — each traced to a primary source, each dated. For enforcement actions specifically, see the regulatory tracker.
- Trial results
- Approvals
- Pricing changes
- Safety findings
-
Acmopatide trims weight and insulin doses in type 1 diabetes in phase 2 trial
Read more: Acmopatide trims weight and insulin doses in type 1 diabetes in phase 2 trialA once-daily injectable dual GLP-1 and GIP agonist, acmopatide (CT-868), reduced body weight by 3.3% to 6.7% over 16 weeks in adults with type 1 diabetes and overweight or obesity, against a 0.3% gain on placebo, according to a phase 2 trial published in Diabetes Care on 28 October 2026. Insulin doses fell and there…
-
Semaglutide linked to fewer atrial fibrillation cases in 94-trial network meta-analysis
Read more: Semaglutide linked to fewer atrial fibrillation cases in 94-trial network meta-analysisA network meta-analysis of 94 randomised trials, published online in Heart Rhythm on 26 October 2026, found that people with type 2 diabetes or obesity who were given subcutaneous semaglutide developed new atrial fibrillation (AF) less often than those given placebo. Dulaglutide pointed the other way. For anyone already taking one of these drugs, nothing…
-
Adding emotion-regulation skills to a teen weight programme cut regain, not loss
Read more: Adding emotion-regulation skills to a teen weight programme cut regain, not lossA randomised trial of 166 parent and teenager pairs, published in JAMA Network Open, found that adding emotion-regulation skills to a standard family-based weight programme made no difference to how much weight adolescents lost during six months of treatment. The difference appeared afterwards: a year after the programme ended, teenagers who had been taught the…
-
Weight lost explained most of the blood-pressure drop across 37 GLP-1 trials
Read more: Weight lost explained most of the blood-pressure drop across 37 GLP-1 trialsAcross 37 phase 3 trials of GLP-1 drugs and newer multi-hormone medicines, the trials that produced more weight loss also produced bigger drops in blood pressure, and differences in weight loss accounted for about three-quarters of the differences in systolic pressure between trials. The pooled analysis, published in EClinicalMedicine on 12 October 2026, covers 50,171…
-
GLP-1 drugs cut short-term eating in a 25-study review, but results vary widely
Read more: GLP-1 drugs cut short-term eating in a 25-study review, but results vary widelyA systematic review published on 19 October 2026 in Obesity Reviews pooled 25 studies of GLP-1-based medicines in 4,060 adults with overweight or obesity and found that the drugs reduced how much people ate in the short term and modestly increased their sense of appetite suppression. The finding is less tidy than it sounds. The…
-
ACSM’s 2027 fitness trends put wearables first and weight management sixth
Read more: ACSM’s 2027 fitness trends put wearables first and weight management sixthWearable technology tops the American College of Sports Medicine’s fitness trends ranking for 2027, the tenth time it has taken the No. 1 spot, according to the college’s annual survey announced on 20 October 2026. Exercise for weight management sits at No. 6, with ACSM noting growing attention to muscle and physical function as obesity…
-
Online tirzepatide programme reports 15.5% loss in 8,127 women
Read more: Online tirzepatide programme reports 15.5% loss in 8,127 womenA study published on 16 October 2026 in Nature Medicine reports outcomes for 8,127 women in the UK who started GLP-1 treatment, almost all of them on tirzepatide, through a structured online programme. Average weight loss at six months was 16.1 kg, or 15.5% of starting weight. It is one of the largest prospective looks…
-
EU regulator backs orforglipron tablet for weight and diabetes
Read more: EU regulator backs orforglipron tablet for weight and diabetesOn 15 October 2026 the European Medicines Agency’s human-medicines committee, the CHMP, recommended that orforglipron, sold as Foundayo, be authorised across the European Union for weight management and for type 2 diabetes. It is a recommendation, not yet an approval: the European Commission still has to adopt it. For readers in the United States nothing…
-
A two-year lifestyle programme changed habits but not weight in 678 older adults
Read more: A two-year lifestyle programme changed habits but not weight in 678 older adultsA two-year lifestyle programme for older adults in German family-doctor practices improved what participants ate and how active they were, but left their body weight no different from that of people who received general advice. The finding, from a new analysis of the AgeWell.de trial in 678 adults aged 60 to 77 with overweight or…
-
Only 30 people have been studied on BPC-157, a systematic review finds
Read more: Only 30 people have been studied on BPC-157, a systematic review findsA systematic review of every published human study of BPC-157 found three, covering 30 people in total, none of them with a control group. All three reported that most participants felt better and none reported a treatment-related side effect, but the authors rated the overall certainty of that evidence as very low. For anyone weighing…